<DOC>
	<DOCNO>NCT00864097</DOCNO>
	<brief_summary>The purpose study investigate analgesic efficacy safety tanezumab add diclofenac SR patient osteoarthritis knee hip currently experience partial benefit , tolerate , diclofenac 150 mg/day therapy .</brief_summary>
	<brief_title>Analgesic Efficacy And Safety Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip</brief_title>
	<detailed_description>This study terminate 16 Nov 2010 follow US FDA clinical hold tanezumab osteoarthritis clinical study halt dose enrollment patient 23 June 2010 potential safety issue .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Osteoarthritis knee hip accord ACR criterion KellgrenLawrence Xray grade equal , great , 2 . Patients must experience benefit current stable dose regimen oral diclofenac 150 mg/day tolerate diclofenac regimen . Pain function level require protocol Screening Baseline . Willing discontinue nonstudy pain medication throughout study except permit per protocol . Willing able comply lifestyle guideline , schedule visit , treatment plan , laboratory test study procedure . Pregnant woman . BMI great 39 . History disease may involve index knee hip include inflammatory joint disease , chrystalline disease ( gout pseudogout ) , endocrinopathies , metabolic joint disease , lupus erythematosus , rheumatoid arthritis ( RA ) , joint infection , neuropathic disorder , avascular necrosis , Paget 's disease tumor . Fibromyalgia , regional pain cause lumbar cervical compression radiculopathy moderate severe pain may confound assessment selfevaluation pain associate OA . Signs symptom clinically significant cardiac disease within 6 month prior screen . Diagnosis TIA within 6 month prior screen diagnosis stroke residual deficit would preclude completion require study activity . History , diagnosis , sign symptom clinically significant neurological and/or psychiatric disease/disorder . At Screening : uncontrolled hypertension , hemoglobin A1c great equal 10 % , ALT AST great equal 3X upper limit normal , creatinine exceed 150 micromol/L men 133 micromol/L woman . Patients warfarin coumadin anticoagulant therapy and/or lithium therapy within 30 day prior Screening . Known hypersensitivity NSAIDs ( eg , diclofenac ) , cyclooxygenase inhibitor paracetamol ( acetaminophen ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Arthritis monoclonal antibody nerve growth factor ( NGF ) anti-NGF tanezumab PF-04383119 RN-624 OA</keyword>
</DOC>